Literature DB >> 26186806

Clinical peculiarities of patients with scleroderma exposed to silica: A systematic review of the literature.

Mayka Freire1, María Alonso2, Alberto Rivera2, Adrián Sousa2, Adriana Soto2, Jose Manuel Gómez-Sousa2, Aida Baroja2, Caritina Vázquez-Triñanes2, Bernardo Sopeña3.   

Abstract

OBJECTIVE: There are few data regarding the existence of clinical differences between patients with systemic sclerosis (scleroderma) exposed to silica (SSc-si) and "idiopathic" cases (SSc-id). Our goal is to describe the clinical characteristics of patients with SSc-si and see if they differ from the SSc-id cases.
METHODS: We performed a systematic review of the literature by searching the MEDLINE, EMBASE and Web of Science databases. We also included our own series of patients diagnosed with SSc-si and SSc-id controls at the "Complejo Hospitalario Universitario de Vigo (CHUVI)" from 1985 to January 2013.
RESULTS: The review of the literature disclosed 32 published series, with clinical data of 254 SSc-si patients (96% males). SSc-si represented 37.5-86% of the scleroderma males and 0-2.7% of the scleroderma females. Globally, more than expected proportion of diffuse forms (61%) and interstitial lung disease (81%) were observed in exposed patients. In the present series, the diagnosis of SSc exposure to silica was recorded in nine patients (9.5%), showing predominance of the diffuse form (77%, p = 0.001), positivity for anti-Scl70 (55%, p = 0.001), presence of ILD (78%, p = 0.048) and lower survival (9.2 versus 15.1, p = 0.023). Diffuse variant remained more prevalent analysing exposed versus non-exposed women (50% versus 8%, p = 0,000) and exposed versus non-exposed men (85.8% versus 50%, p = 0,000).
CONCLUSION: Silica exposure is a predominant risk factor in male SSc populations. The review of the literature is consistent with an association of SSc-si and diffuse scleroderma. A trend toward lower survival was observed in our series in SSc-si group.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ASIA; Autoimmune/inflammatory syndrome induced by adjuvants; Epidemiology; Occupational disease; Scleroderma; Silica; Systematic review; Systemic sclerosis

Mesh:

Substances:

Year:  2015        PMID: 26186806     DOI: 10.1016/j.semarthrit.2015.06.004

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  7 in total

Review 1.  Occupational and environmental scleroderma. Systematic review and meta-analysis.

Authors:  Manuel Rubio-Rivas; Rafael Moreno; Xavier Corbella
Journal:  Clin Rheumatol       Date:  2017-01-14       Impact factor: 2.980

Review 2.  Biomaterials to Mimic and Heal Connective Tissues.

Authors:  Benjamin R Freedman; David J Mooney
Journal:  Adv Mater       Date:  2019-03-25       Impact factor: 30.849

3.  Geographic disparity in systemic sclerosis mortality in the United States: 1999-2017.

Authors:  Alicia Rodriguez-Pla; Robert W Simms
Journal:  J Scleroderma Relat Disord       Date:  2019-08-26

4.  Three's Company: Coexistence of Silicosis, Scleroderma, and Sjogren Syndrome in a Single Patient.

Authors:  Alexis Ziebelman; Shir Raibman-Spector; Omer Gendelman
Journal:  Case Rep Rheumatol       Date:  2022-05-27

5.  High prevalence of occupational exposure to solvents or silica in male systemic sclerosis patients: a Belgian cohort analysis.

Authors:  Evelien De Decker; Marie Vanthuyne; Daniel Blockmans; Frederic Houssiau; Jan Lenaerts; Rene Westhovens; Benoit Nemery; Ellen De Langhe
Journal:  Clin Rheumatol       Date:  2018-02-23       Impact factor: 2.980

6.  Systemic sclerosis due to crystalline silica exposure among jewelry workers in Korea: two case reports.

Authors:  Jae Yoon Kim; Sang Yoon Do; Young Hoon Moon; Chul Gab Lee; Yun Sung Kim; Byung Soon Choi; Eun-A Kim; Han Soo Song
Journal:  Ann Occup Environ Med       Date:  2017-06-19

7.  Erasmus Syndrome: Association of Silicosis and Systemic Sclerosis.

Authors:  Reena K Sharma; Anjna K Sharma; Anuj Sharma
Journal:  Indian Dermatol Online J       Date:  2018 May-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.